Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group

Prospective trials are required to clarify the role of ctDNA as a valid surrogate end point for progression-free or overall survival in GI cancers.

Authors

Institutions

Publication Details

Journal
JCO Precision Oncology
Published
2025-03-01
DOI
https://doi.org/10.1200/po-24-00489
Citations
3
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
2.81

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group

Daniela Molena, Michael K. Gibson, Anup Kasi, Kelsey A. Klute et al.
3 citations
JCO Precision Oncology
Cancer Genomics and Diagnostics
2.81
article

Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group

Daniela Molena, Michael K. Gibson, Anup Kasi, Kelsey A. Klute, Cathy Eng, Van Karlyle Morris, Lakshmi N. Rajdev, Philip A. Philip, Christopher H. Lieu, Arvind N. Dasari, Thomas J. George, Nataliya V. Uboha, Akhil Chawla, Aparna R. Parikh, Mark H. O’Hara, Theodore Sunki Hong, Gregory P. Botta, Dustin A. Deming, Karyn A. Goodman, Midhun Malla, Daniel A. King, Stacey A. Cohen, Salma K. Jabbour, Carmen J. Allegra, Samuel Jacob Klempner, Gentry Teng King, Jennifer R. Eads, Shubham Pant, Manish A. Shah, Andrew M. Lowy, Kristen Spencer
article en
3 citations

Abstract

Prospective trials are required to clarify the role of ctDNA as a valid surrogate end point for progression-free or overall survival in GI cancers.

JCO Precision OncologyVol. 9(9)
Rutgers, The State University of New Jersey (US), Northwestern University (US), Northwell Health (US), Feinstein Institute for Medical Research (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), University of Wisconsin–Madison (US), Harvard University (US), Wayne State University (US), University of Washington (US), Cornell University (US), University of Florida Health (US), University of Alabama at Birmingham (US), University of California San Diego (US), Massachusetts General Hospital (US), Fred Hutch Cancer Center (US), Presbyterian Hospital (US), University of Kansas Medical Center (US), University of Colorado Cancer Center (US), National Cancer Institute (US), UF Health Cancer Center, New York University (US), University of Nebraska Medical Center (US), University of Pennsylvania (US), University of Colorado Denver (US), Icahn School of Medicine at Mount Sinai (US)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Gilead Sciences, American Society of Clinical Oncology, FibroGen, Lantheus Medical Imaging, Boston Scientific Corporation, Regeneron Pharmaceuticals, Taiho Pharmaceutical, Exelixis, Jazz Pharmaceuticals, Cholangiocarcinoma Foundation, Celldex Therapeutics, Novocure, US WorldMeds, Parker Institute for Cancer Immunotherapy, Nihon Medi-Physics, Mersana Therapeutics, Mirati Therapeutics, BeiGene, Incyte, Syndax Pharmaceuticals, Cardinal Health, NGM Biopharmaceuticals, Revolution Medicines, Seagen, Natera, Eisai, Astellas Pharma, European Society for Medical Oncology, Ipsen, Bavarian Nordic, Geistlich Pharma, Genentech, EMD Serono, Foundation Medicine, Daiichi Sankyo Europe
Openalex Percentile: Top 11%
Cancer Genomics and Diagnostics
2.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.